Is AnaptysBio, Inc. (ANAB) a Buy, Sell, or Hold?
AnaptysBio, Inc.
NASDAQ:ANAB
$55.82 USD
-$6.69 (-10.7%)
- Volume
- 1.54M
- Average Volume
- 674.8K
- Market Capitalization
- $2.41B
- P/E Ratio
- -65.67
- Dividend Yield
- 0.00%
- Price Target
- $75.50
- Year High
- $72.36
- Year Low
- $11.40
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.58
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Daniel Faga |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ANAB |
| CUSIP | 032724106 |
| CIK | 0001370053 |
| Web | https://www.anaptysbio.com |
| Phone | 858 362 6295 |
| Currency | USD |
| Employees | 104 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 21.76 |
| Payout Ratio | 0.00 |
| Current Ratio | 7.58 |
| Quick Ratio | 7.58 |
| Cash Ratio | 5.96 |
Sales & Book Value
| Annual Sales | $234.6M |
| Price / Sales | 10.36 |
| Cash Flow | 0.15 |
| Price / Cash Flow | 545.95 |
| Price / Book | 125.64 |
Price Target and Rating
| Average Stock Price Forecast | $75.50 |
| High Stock Price Forecast | $90.00 |
| Low Stock Price Forecast | $50.00 |
| Forecast Upside/Downside | -26.07% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 22 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.46 |
| Trailing P/E Ratio | -65.67 |
| PEG Ratio | 0.18 |
| P/E Growth | 0.18 |
| Net Income | $-13.23M |
| Net Margin | -11.53% |
| Pretax Margin | -11.46% |
| Return on Equity | 442.91% |
| Return on Assets | -8.13% |
Financials Score
| AltmanZ Score | 4.46 |
| Piotroski Score | 5.00 |
| Working Capital | 274.41M |
| Total Assets | 329.68M |
| Ebit | 56.06M |
| Market Cap | 3.01B |
| Total Liabilities | 316.94M |
Poll Results
About AnaptysBio, Inc. (NASDAQ:ANAB) Stock
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 ... development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer
2026-07-14 09:31:09
GSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal cancer, supporting potential regulatory filings.
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?
2026-05-21 10:40:32
Here is how AnaptysBio, Inc. (ANAB) and Electromed, Inc. (ELMD) have performed compared to their sector so far this year.
Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?
2026-05-19 10:55:45
The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
2026-05-14 10:55:42
After losing some value lately, a hammer chart pattern has been formed for AnaptysBio (ANAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
2026-05-12 16:15:00
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
2026-05-11 09:15:00
SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced the appointment of Christopher Murphy as Chief Financial Officer and Owen Hughes as a member of its Board of Directors.
AnaptysBio, Inc. (ANAB) is a Great Momentum Stock: Should You Buy?
2026-05-06 13:01:06
Does AnaptysBio, Inc. (ANAB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?
2026-05-05 10:41:32
Here is how AnaptysBio, Inc. (ANAB) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.
Frequently Asked Questions
-
What is the current AnaptysBio, Inc. (ANAB) stock price?
-
AnaptysBio, Inc.(NASDAQ:ANAB) stock price is $55.82 in the last trading session. During the trading session, ANAB stock reached the peak price of $72.36 while $11.404 was the lowest point it dropped to. The percentage change in ANAB stock occurred in the recent session was --10.7% while the dollar amount for the price change in ANAB stock was -$-6.69.
-
ANAB's industry and sector of operation?
-
The NASDAQ listed ANAB is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ANAB?
-
Priya Raina | Senior Vice President of Clinical Operations
John Kwon | Vice President of GI Clinical Development
Monique Da Silva | Senior Vice President of Corporate Affairs
Martin Dahl | Senior Vice President of Research
Benjamin Stone | Chief Business Officer -
How many employees does ANAB have?
-
Number of ANAB employees currently stands at 104. ANAB operates from 10770 Wateridge Circle, San Diego, CA 92121-5801, US.
-
Link for ANAB official website?
-
Official Website of ANAB is: https://www.anaptysbio.com
-
How do I contact ANAB?
-
ANAB could be contacted at phone #858 362 6295 and can also be accessed through its website. ANAB operates from 10770 Wateridge Circle, San Diego, CA 92121-5801, US.
-
How many shares of ANAB are traded daily?
-
The average number of ANAB shares traded daily for last 3 months was 674.8K.
-
What is the market cap of ANAB currently?
-
The market value of ANAB currently stands at $2.41B with its latest stock price at $55.82